Niyad™ (nafamostat mesylate)
Regional anticoagulation for Continuous Renal Replacement Therapy (CRRT)/Intermittent Hemodialysis (IHD)
Key Facts
About Talphera
Talphera is a publicly traded biopharma focused on developing and commercializing innovative therapies for medically supervised settings, having transformed from AcelRx Pharmaceuticals in 2023. Its core strategy revolves around nafamostat mesylate, a molecule with anticoagulant, anti-inflammatory, and antiviral properties, initially targeting anticoagulation during dialysis with its lead candidate Niyad™. With Niyad's Phase 3 data expected by end of 2025 and a pipeline of follow-on nafamostat indications and hospital-ready prefilled syringes, Talphera aims to address significant gaps in hospital-based care. The company's approach is validated by nafamostat's decades of use in Asia and a strategic partnership with Laboratoire Aguettant.
View full company profile